The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden
- 305 Downloads
This paper assessed the cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden, using one model and a societal perspective. Cost-effective scenarios were found in all these chronic disorders. These findings are of relevance for decisions on the efficient allocation of health care resources.
There is a need to assess the cost-effectiveness (CE) of treatment of osteoporosis from a societal perspective and to relate this to the CE of interventions in other disease areas. This is of relevance for decisions on the efficient allocation of health care resources within and between disease areas. The purpose of the paper was to estimate the CE of the treatment and prevention of osteoporosis and to put that into the perspective of treating hypertension and hyperlipidaemia. The CE was assessed for different high risk female populations aged 50–80 years.
The estimation of CE was based on a model populated with data for Sweden.
Compared to no intervention, a 5-year treatment of osteoporosis, hypertension, and hyperlipidaemia, is cost effective for most of the assessed high risk female populations. The cost per gained quality adjusted life year (QALY) for the treatment of a 70-year-old woman never exceeded SEK 330,000 (US$ 44,000), which is generally judged as an acceptable cost for a gained QALY.
The study demonstrates that it is possible to produce reliable estimates of the CE of treatments in different disease areas within the context of a single model.
KeywordsBisphosphonates Cost Hydrochlorthiazides QALY Statins
Supported by a grant from the International Osteoporosis Foundation.
Conflicts of interest
- 7.Zethraeus N, Borgström F, Jönsson B, Kanis J (2004) A reassessment of the cost-effectiveness of hormone replacement therapy in Sweden - results based on the Women’s Health Initiative randomised controlled trial. Working Paper Series in Economics and Finance at the Stockholm School of Economics, 2004, Working paper No 571 http://swopec.hhs.se/hastef/papers/hastef0571.pdf
- 8.Stevenson M, Jones ML, Davis S, Beverly C (2005) Extract from DSU report: Osteoporosis - primary prevention. http://wwwniceorg.uk/pageaspx?o=273738
- 10.Greenspan SL, Emkey RD, Bone HG, Weiss SR et al (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:875–883CrossRefPubMedGoogle Scholar
- 13.SBU (1994) [The Swedish Council on Technology Assessment in Health Care]. Moderately elevated blood pressure. Report No 121. StockholmGoogle Scholar
- 14.SBU (2004) [The Swedish Council on Technology Assessment in Health Care]. Moderately elevated blood pressure - a systematic review. Report No 170. StockholmGoogle Scholar
- 17.Jönsson B, Hedbrant J, Johnell O (1993) A computer simulation model to analyse the cost-effectiveness of fracture prevention of osteoporosis. EFI Research paper Nr 6525Google Scholar
- 19.Strom O, Borgstrom F, Zethraeus N, Johnell O et al (2007) Long term costs and quality of life associated with osteoporosis related fractures in Sweden. accepted in Acta Orthopaedica (September)Google Scholar
- 22.Hellenius M, Rosell M, Sandgren J (2000) High prevalence of overweight and metabolic syndrome among 60 year old women and men in Stockholm, Sweden. 12th International Symposium on Atherosclerosis StockholmGoogle Scholar
- 28.NCEP (2002) Third report of the National Cholesterol Education Program. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421Google Scholar
- 29.WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Study Group. World Health Organ Tech Rep Ser 843:1–129Google Scholar
- 30.FASS för förskrivare. Accessed [2006-11-24] http://www.fass.se
- 35.SBU (2003) [The Swedish Council on Technology Assessment in Health Care]. Osteoporosis - prevention, diagnosis and treatment. Report No 165. StockholmGoogle Scholar